CAJ | 학술논문

目的：探讨康柏西普对年龄相关性黄斑变性患者外周血血管内皮生长因子、眼压及视力变化的影响。方法收集唐山工人医院收治的年龄相关性黄斑变性患者60例，随机分为实验组和对照组，每组各30例，对照组给予雷珠单抗注射液玻璃体腔内注射，实验组给予康柏西普眼用注射液柏玻璃体腔内注射，每月1次，均治疗3个月，治疗结束后，对所有患者的血清VEGF、CRP含量、CMT、CNV水平及荧光素渗漏率、眼压和视力进行检测。结果治疗后，与对照组比较，实验组患者的血清VEGF含量明显较低（P＜0．05）；实验组患者的血清CRP含量明显较低（P＜0．05）；实验组患者的CMT、CNV水平及荧光素渗漏率明显较低（P＜0．05）；实验组患者的视力（ logMAR）及IOP水平明显较低（ P＜0．05）。结论康柏西普眼用注射液能够降低年龄相关性黄斑变性患者外周血VEGF、CRP含量，减少CMT、CNV水平及荧光素渗漏率，降低眼压，改善视力。
목적：탐토강백서보대년령상관성황반변성환자외주혈혈관내피생장인자、안압급시력변화적영향。방법수집당산공인의원수치적년령상관성황반변성환자60례，수궤분위실험조화대조조，매조각30례，대조조급여뢰주단항주사액파리체강내주사，실험조급여강백서보안용주사액백파리체강내주사，매월1차，균치료3개월，치료결속후，대소유환자적혈청VEGF、CRP함량、CMT、CNV수평급형광소삼루솔、안압화시력진행검측。결과치료후，여대조조비교，실험조환자적혈청VEGF함량명현교저（P＜0．05）；실험조환자적혈청CRP함량명현교저（P＜0．05）；실험조환자적CMT、CNV수평급형광소삼루솔명현교저（P＜0．05）；실험조환자적시력（ logMAR）급IOP수평명현교저（ P＜0．05）。결론강백서보안용주사액능구강저년령상관성황반변성환자외주혈VEGF、CRP함량，감소CMT、CNV수평급형광소삼루솔，강저안압，개선시력。
Objective To analysis the effect of conbercept ophthalmic injection on peripheral blood vascular endothelial growth factor,intraocular pressure and visual acuity in patients with age related macular degeneration.Methods 60 patients who were diagnosed with age related macular degeneration were collected.All patients were randomly divided into experimental group and control group,30 cases in each group, lucentis intravitreal injection was given into the vitreous cavity in control group, experimental group give conbercept injection into the vitreous cavity,once a month.All patients were treated for 3 months,after the end of treatment,all patients serum VEGF and CRP,CMT,CNV and fluorescence leakage rate,intraocular pressure and visual acuity were detected.ResuIts After treatment,compared with control group,the content of serum VEGF was significantly lower in the experimental group(P<0.05).The content of serum CRP was significantly lower in experimental group(P<0.05).The CMT,CNV and fluorescence leakage rate were significantly lower in the experimental group (P<0.05).The level of IOP and visual acuity(logMAR)were significantly lower in the experimental group (P<0.05).ConcIusions Conbercept ophthalmic injection can reduce age-related macular degeneration patients week blood VEGF and CRP levels and decrease the CMT, CNV and fluorescence leakage rate, reduce intraocular pressure, visual acuity improvement and have guiding significance for clinic.